Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

(2020) Caron A. Jacobson et al.   JOURNAL OF CLINICAL ONCOLOGY

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

Metabolic Barriers to T Cell Function in Tumors

(2018) Ayaka Sugiura et al.   JOURNAL OF IMMUNOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use

(2017) Dominik Lock et al.   HUMAN GENE THERAPY

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells

(2017) Michael Schmueck-Henneresse et al.   JOURNAL OF IMMUNOLOGY

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversing T-cell Dysfunction and Exhaustion in Cancer

(2016) H. M. Zarour   CLINICAL CANCER RESEARCH

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

(2016) Nathan Singh et al.   Science Translational Medicine

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET